stem cells

Court Ruling Pressures Stem Cell Stocks

Following Monday's ruling in the Federal District Court for Washington, D.C., to block federal funding for research that uses human embryonic stem cells, companies researching and developing medical techniques involving stem cells saw shares tumble down today across the board.

Stem Cell Therapies: Is Now the Time to Invest?

For investors on the hunt for groundbreaking technologies, stem cell therapies originally looked promising. But while the world waited for research to transform into treatments, Wall Street largely lost interest. Now, the science is accelerating, but stock prices haven't caught up. Is today your chance to make a killing on healing?

Pfizer Invests in Stem Cell Therapy

Long an old-line drug company, Pfizer is looking increasingly like a new biotech these days, especially after licensing a stem cell therapy. Athersys' MultiStem is a therapy that consists of a special class of stem cells obtained from the bone marrow of healthy, adult donors to treat inflammatory bowel disease.